Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report

A. Cuneo, L. Scarfò, G. Reda, M. Varettoni, F.M. Quaglia, M. Marchetti, L. De Paoli, F. Re, D. Pietrasanta, G.M. Rigolin, L. Orsucci, A. Ibatici, V. Gattei, F.R. Mauro, L. Trentin, L. Laurenti, R. Marasca, R. Foà, I. Angeletti, F. ChiurazziG. Del Poeta, M. Rosaria De Paolis, L. Farina, A. Ferrari, M. Gentile, D. Gottardi, A. Gozzetti, M. Leone, L. Levato, M. Maccaferri, L. Malerba, M. Motta, R. Murru, L. Nocilli, J. Olivieri, V. Stefoni, Campus CLL working group

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)763-766
Number of pages4
JournalBlood
Volume136
Issue number6
DOIs
Publication statusPublished - 2020

Keywords

  • ibrutinib
  • immunosuppressive agent
  • cancer incidence
  • cancer therapy
  • chronic lymphatic leukemia
  • coronavirus disease 2019
  • human
  • immunosuppressive treatment
  • Italy
  • Letter
  • manual ventilation
  • mortality
  • pandemic
  • Philadelphia chromosome positive cell
  • prevalence
  • priority journal
  • questionnaire
  • throat culture
  • Waldenstroem macroglobulinemia
  • aged
  • Betacoronavirus
  • complication
  • Coronavirus infection
  • disease management
  • isolation and purification
  • middle aged
  • very elderly
  • virus pneumonia
  • Aged
  • Aged, 80 and over
  • Coronavirus Infections
  • Disease Management
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral

Cite this